Cargando…

Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study

BACKGROUND: Chronic inflammation has been described in people living with HIV (PLHIV) receiving antiretroviral therapy (ART) despite viral suppression. Inflammation associated non-communicable diseases, including atherosclerosis, are becoming recognized complication of HIV infection. We studied the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Srichatrapimuk, Sirawat, Wongsa, Artit, Sungkanuparph, Somnuek, Kiertiburanakul, Sasisopin, Tassaneetrithep, Boonrat, Phuphuakrat, Angsana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969700/ https://www.ncbi.nlm.nih.gov/pubmed/36849967 http://dx.doi.org/10.1186/s12981-023-00506-2

Ejemplares similares

Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study
por: Wongprikorn, Asita, et al.
Publicado: (2016)

Clinical features of adult patients with a definite diagnosis of central nervous system tuberculosis in an endemic country: A 13-year retrospective review
por: Kirdlarp, Suppachok, et al.
Publicado: (2020)

Efficacy of Rilpivirine-Based Regimens as Switch Therapy From Nevirapine-Based Regimens in Human Immunodeficiency Virus-Infected Patients With Virological Suppression: A Randomized Controlled Trial
por: Petchkum, Porkaew, et al.
Publicado: (2019)

Immune response to influenza vaccination in ESRD patients undergoing hemodialysis vs. hemodiafiltration
por: Nongnuch, Arkom, et al.
Publicado: (2020)

Prevalence of HIV infection, access to HIV care, and response to antiretroviral therapy among partners of HIV-infected individuals in Thailand
por: Kiertiburanakul, Sasisopin, et al.
Publicado: (2018)

Risk Factors of Renal Tubular Dysfunction in Thai People Living with HIV Receiving Tenofovir Disoproxil Fumarate
por: Phuphuakrat, Angsana, et al.
Publicado: (2022)

Detectable Duration of Viable SARS-CoV-2, Total and Subgenomic SARS-CoV-2 RNA in Noncritically Ill COVID-19 Patients: a Prospective Cohort Study
por: Phuphuakrat, Angsana, et al.
Publicado: (2022)

Integrated therapy for HIV and cryptococcosis
por: Srichatrapimuk, Sirawat, et al.
Publicado: (2016)

Tuberculous Panophthalmitis with Lymphadenitis and Central Nervous System Tuberculoma
por: Srichatrapimuk, Sirawat, et al.
Publicado: (2016)

SARS-CoV-2 RT-PCR positivity of individuals subsequent to completing quarantine upon entry into a country during a transmission-free period
por: Srichatrapimuk, Sirawat, et al.
Publicado: (2022)

Missed opportunities for earlier diagnosis of HIV infection in people living with HIV in Thailand
por: Phuphuakrat, Angsana, et al.
Publicado: (2022)

Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure
por: Manosuthi, Weerawat, et al.
Publicado: (2009)

Cardiac implantable electronic device infection in the cardiac referral center in Thailand: incidence, microbiology, risk factors, and outcomes
por: Korkerdsup, Theerawat, et al.
Publicado: (2018)

Prediabetes among HIV-infected individuals receiving antiretroviral therapy: prevalence, diagnostic tests, and associated factors
por: Phuphuakrat, Angsana, et al.
Publicado: (2020)

EFFICACY AND SAFETY OF LOW DOSE COLCHICINE ON SURROGATE MARKERS OF CARDIOVASCULAR EVENTS IN PEOPLE LIVING WITH HIV RECEIVING ANTIRETROVIRAL THERAPY
por: Korkerdsup, Theerawat, et al.
Publicado: (2022)

1697 Prevalence and associated factors of infection with drug-resistant Mycobacterium tuberculosis in Thailand
por: Chutanan, Chompunut, et al.
Publicado: (2014)

Emergence of HIV-1 drug resistance mutations among antiretroviral-naïve HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand
por: Sungkanuparph, Somnuek, et al.
Publicado: (2012)

Seroprevalence of Zika virus in pregnant women from central Thailand
por: Phatihattakorn, Chayawat, et al.
Publicado: (2021)

Correction: Seroprevalence of Zika virus in pregnant women from central Thailand
por: Phatihattakorn, Chayawat, et al.
Publicado: (2021)

Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
por: Nishijima, Takeshi, et al.
Publicado: (2013)

Comparison between blood hemoglobin concentration determined by point-of-care device and complete blood count in adult patients with dengue
por: Wisanuvej, Kantasit, et al.
Publicado: (2021)

Association between gut microbiota and prediabetes in people living with HIV
por: Jayanama, Kulapong, et al.
Publicado: (2022)

Rapid CD4 decline after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy in a resource-limited setting
por: Sungkanuparph, Somnuek, et al.
Publicado: (2007)

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers
por: Dickinson, Laura, et al.
Publicado: (2009)

Is Ritonavir-Boosted Atazanavir a Risk for Cholelithiasis Compared to Other Protease Inhibitors?
por: Hamada, Yohei, et al.
Publicado: (2013)

The association between body mass index and severity of Coronavirus Disease 2019 (COVID-19): A cohort study
por: Jayanama, Kulapong, et al.
Publicado: (2021)

Spontaneous tension hemothorax in a severe COVID-19 patient receiving ECMO therapy: The other side of COVID-19-associated coagulopathy
por: Thammavaranucupt, Kanin, et al.
Publicado: (2022)

Increased platelet activation and lower platelet-monocyte aggregates in COVID-19 patients with severe pneumonia
por: Srihirun, Sirada, et al.
Publicado: (2023)

Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure
por: Manosuthi, Weerawat, et al.
Publicado: (2012)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
por: Antoniou, Tony, et al.
Publicado: (2017)

A Model and Risk Score for Predicting Nevirapine-Associated Rash among HIV-infected Patients: In Settings of Low CD4 Cell Counts and Resource Limitation
por: Kiertiburanakul, Sasisopin, et al.
Publicado: (2009)

Prevalence of Primary HIV Drug Resistance in Thailand Detected by Short Reverse Transcriptase Genotypic Resistance Assay
por: Kiertiburanakul, Sasisopin, et al.
Publicado: (2016)

Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia
por: Sasaki, Jun
Publicado: (2010)

Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
por: Montanha, Maiara Camotti, et al.
Publicado: (2021)

Response of Severe EV71-Infected Patients to Hyperimmune Plasma Treatment: A Pilot Study
por: Techasaensiri, Chonnamet, et al.
Publicado: (2021)

Durability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3)
por: Boongird, Sarinya, et al.
Publicado: (2022)

SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile
por: Vacharathit, Vimvara, et al.
Publicado: (2021)

CoronaVac induces lower neutralising activity against variants of concern than natural infection
por: Vacharathit, Vimvara, et al.
Publicado: (2021)

Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
por: Overton, T, et al.
Publicado: (2010)

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study
por: Squires, Kathleen E., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_pbsuqih7cbivjnj26cj013f7pn